Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

ONC vs MRNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ONC Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 7–3 Matrix Metrics)

ONC Overall Winner 6-Pillar Tally: ONC 3 – 3 MRNA Matrix Metrics: ONC 7 – 3 MRNA

As of Nov 20, 2026, BeOne Medicines Ltd. (ONC) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ONC carries a Unified Composite Score of 48.0/100 (HOLD) at $390.94 (36.2x Forward P/E, 17.8% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ONC vs MRNA
ONC NASDAQ Head-to-Head Winner
BeOne Medicines Ltd. American Depositary Shares
Pharmaceutical Preparations
$390.94
-2.19% 1D
Market Cap $45.7B
TTM Revenue $6.61B
Forward P/E 36.2x
Beta / 30D Vol 0.67β · 37% Vol
Unified Composite Score
48.0 / 100 HOLD
Tech 34.0 Fund 43.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 50
RSI-14: 50.0 · SMA20: $392.65 · SMA50: $374.57
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$195.00
-2.17% 1D
Market Cap $80.7B
TTM Revenue $2.52B
Forward P/E 23.0x
Beta / 30D Vol 2.23β · 78% Vol
Unified Composite Score
40.3 / 100 SELL
Tech 18.0 Fund 42.0 Flow 67.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 41.5 · SMA20: $225.26 · SMA50: $207.89

6-Pillar Scorecard Institutional Category Breakdown (ONC 3 – 3 MRNA)

Columns: Metric · ONC · MRNA
1. Valuation Multiples MRNA
Forward P/E 36.2x 23.0x
Trailing P/E 51.2x 23.0x
PEG Ratio 0.71x N/M
EV / Revenue 6.9x 33.1x
2. Growth & Scale ONC
Revenue Growth (YoY) +33.8% +29.2%
Earnings Growth (YoY) +212.5% -85.1%
TTM Revenue (USD) $6.61B $2.52B
Market Cap $45.7B $80.7B
3. Profitability & Quality ONC
Gross Margin 89.4% -42.0%
Operating Margin 17.8% -80.8%
Net Profit Margin 13.9% -110.5%
Return on Equity (ROE) 18.4% -34.5%
4. Balance Sheet & Cash Flow ONC
Cash Generation (TTM) $1.33B EBITDA -$2.04B
Cash Flow Margin 20.1% EBITDA Mgn -81.0%
Net Cash / Leverage $51.01 Book/Sh · 18.4% ROE $3.03B Net Debt (0.62x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MRNA
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile 45.8% (23rd %ile) 89.6% (52nd %ile)
Put/Call OI Skew Thin ADR Chain 1.05x (Balanced)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat MRNA
OpEx & R&D Intensity 71.6% of Rev ($4.73B) 38.8% of Rev ($980M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ONC (7) vs MRNA (3)
Institutional Metric ONC MRNA Criterion Row Edge
Market Capitalization
Scale
$45.7B $80.7B Larger Scale MRNA
Trailing P/E Ratio
Valuation
51.2x 23.0x Lower Multiple MRNA
Forward P/E Ratio
Valuation
36.2x 23.0x Lower Multiple MRNA
Revenue Growth (YoY)
Growth
+33.8% +29.2% Higher Growth ONC
Operating Margin (TTM)
Profitability
17.8% -80.8% Higher Margin ONC
Net Profit Margin
Profitability
13.9% -110.5% Higher Margin ONC
Return on Equity (ROE)
Capital Efficiency
18.4% -34.5% Higher ROE ONC
52-Week Range Position
Momentum
80% ($254–$425) 67% ($22–$281) Stronger Trend ONC
Beta / 30D Volatility
Risk Regime
0.67β · 37% Vol 2.23β · 78% Vol Lower Realized Risk ONC
Unified Institutional Score
Composite Signal
48.0 / 100 (HOLD) 40.3 / 100 (SELL) Higher Composite ONC
Trailing 12M Revenue (USD)
Operating Scale
$6.61B $2.52B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
89.4% -42.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.71x PEG · 6.9x EV/Rev N/M PEG · 33.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$1.33B EBITDA ($51.01 Book/Sh · 18.4% ROE) -$2.04B ($3.03B Net Debt (0.62x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ONC +6.04 pp
ONC: +2.27% · MRNA: -3.77%
3M Horizon MRNA +35.3 pp
ONC: +5.1% · MRNA: +40.4%
6M Horizon MRNA +289.95 pp
ONC: +26.01% · MRNA: +315.96%
1Y Horizon MRNA +695.95 pp
ONC: +10.5% · MRNA: +706.45%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ONC vs MRNA. Trailing 12-month operating profitability (ONC 17.8% vs MRNA -80.8%) and valuation multiples (ONC 36.2x vs MRNA 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.

ONC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$6.61B
Gross Margin89.4%
Op. Margin17.8%
ROE / Fwd P/E18.4% · 36.2x
MRNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.52B
Gross Margin-42.0%
Op. Margin-80.8%
ROE / Fwd P/E-34.5% · 23.0x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ONC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 45.8%
IV Percentile 23rd %ile
Put/Call OI Skew Thin ADR Chain
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ONC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
MRNA CONSOLIDATION
22d in phase · OBV DISTRIBUTION
Current IV 89.6%
IV Percentile 52nd %ile
Put/Call OI Skew 1.05x (Balanced)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact MRNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $215.27 · IV 83.7%

MRNA Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($21,527)

Compare $21,527 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 83.7% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $220 / $260 Bull Call Spread

Buy 1x $220C · Sell 1x $260C · 32d

Net Entry $1,105 Debit
T+5d @ +5% Move +$267 (+24%)
Max Risk / Buffer $1,105 Capped
5d Edge & Liquidity 0.7x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Dec 18 $190 / $180 Bull Put Spread

Sell 1x $190P · Buy 1x $180P · 32d

Net Entry $255 Credit
Max Credit / Yield +$255 (+34.2% RoM)
Max Risk / Buffer -12.9% Cushion ($745 Mgn)
5d Edge & Liquidity 74% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq A

Dec 18 $190P / $220-$260C Seagull

Sell 1x $190P · Buy 1x $220/$260C · 32d

Net Entry $140 Debit
T+5d @ +5% Move +$693 (+23.1% RoM)
Max Risk / Buffer -11.7% Put Cushion ($3,005 Mgn)
5d Edge & Liquidity 1.1x R:R · Liq A
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ONC Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $45.7B market capitalization and 17.8% operating margin.
OpEx & R&D Reinvestment 71.6% of Rev ($4.73B)
90D Engineering Disclosures 0 Published
MRNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $80.7B market capitalization and -80.8% operating margin.
OpEx & R&D Reinvestment 38.8% of Rev ($980M)
90D Engineering Disclosures 0 Published · mRNA Therapeutics

Investor FAQ ONC vs MRNA Key Questions & Quantitative Answers

As of Nov 20, 2026, BeOne Medicines Ltd. (ONC) is the stronger overall head-to-head candidate over Moderna, Inc. (MRNA) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). ONC carries a Unified Composite Score of 48.0/100 (HOLD) at $390.94 (36.2x Forward P/E, 17.8% operating margin), whereas MRNA carries 40.3/100 (SELL) at $195.00 (23.0x Forward P/E, -80.8% operating margin). Technically, ONC sits in a Neutral phase (RSI 50.0, UNCLASSIFIED options structure) and MRNA sits in a Neutral phase (RSI 41.5, CONSOLIDATION options structure).

ONC leads the Growth & Scale pillar: ONC posts +33.8% YoY revenue growth and +212.5% YoY earnings growth on $6.61B TTM revenue (89.4% gross margin, 17.8% operating margin), compared with MRNA at +29.2% YoY revenue growth and -85.1% YoY earnings growth on $2.52B TTM revenue (-42.0% gross margin, -80.8% operating margin). On trailing 12-month operating scale, ONC generates $6.61B in USD-normalized revenue versus $2.52B for MRNA. In operating R&D and SG&A reinvestment, ONC deploys 71.6% of Rev ($4.73B) (0 90-day corporate R&D disclosures) versus 38.8% of Rev ($980M) (0 disclosures) for MRNA.

MRNA screens cheaper on headline valuation multiples. ONC trades at 36.2x Forward P/E, 51.2x Trailing P/E, 0.71x PEG, and 6.9x EV/Revenue (20.1% EBITDA margin), whereas MRNA trades at 23.0x Forward P/E, 23.0x Trailing P/E, N/M PEG, and 33.1x EV/Revenue (-81.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ONC (18.4% ROE) versus MRNA (-34.5% ROE) capital efficiency.

In options market volatility and institutional positioning, ONC carries 45.8% implied volatility (23rd %ile, Compressed (<25th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.67β · 37% Vol realized risk). By comparison, MRNA carries 89.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), a 1.05x (Balanced) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (2.23β · 78% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.